TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Marengo Therapeutics and Ipsen Collaborate to Select Initial Oncology Drug Candidate

Tuesday, April 02, 2024

Marengo Therapeutics, Inc., a clinical-stage biotech firm pioneering a novel approach to activate T cells targeting the Vβ chain of the T cell receptor (TCR), has made a significant announcement regarding its collaboration with Ipsen (Euronext: IPN; ADR: IPSEY) in the field of oncology. Together, they have reached a milestone by nominating the first clinical drug candidate (DC) out of the two planned under their partnership.

This achievement marks the culmination of a productive collaboration since the strategic partnership was initiated in August 2022. The collaborative efforts between Marengo and Ipsen aim to advance the program through IND-enabling studies and into clinical development. This DC nomination signifies the initiation of the selective T cell activation repertoire (STAR) T cell bi-functional activator programs, which are integral to their joint endeavor.

Dr. Zhen Su, Chief Executive Officer of Marengo, commended the close partnership with Ipsen and highlighted the expertise and dedication of Marengo's R&D team. He emphasized the potential of their STAR TCR Vb T cell activator platform to develop a new class of precision T cell bispecific antibodies for refractory solid tumors. Dr. Su looks forward to advancing treatment options for cancer patients in the next phase of the collaboration.

As per the agreement, Marengo will receive a milestone payment for achieving this predefined preclinical milestone. Marengo leads the research and preclinical development efforts, while Ipsen is responsible for regulatory submissions, clinical development, and eventual commercialization.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit